What needs to happen to increase access to MDR-TB treatment?
Scaling up access to MDR-TB treatment is not easy, but it’s possible. To achieve the global target of 1.6 million patients treated by 2015, we’re going to need better tests and better drugs. The increasing number of people that have MDR- or XDR-TB was a catastrophe foreseen – because no new drugs have been developed in decades. TB is a disease that hits the poor hardest, and because of that there’s little prospect of commercial rewards if you develop a new TB drug, for example. This means medical research into TB has long been neglected and the diagnostics, drugs and vaccines that we have today are completely inadequate – the tests for example, miss many more of the people living with HIV/AIDS and who also have TB than they detect. There are current efforts to develop new drugs, diagnostics and vaccines and they are important, but they are far from sufficient. So what does the resolution mean for TB research? In the resolution, countries again emphasized that alternative financing mech
Related Questions
- Are there treatment interventions that can effectively respond to the mental health needs of youth in the juvenile justice system?
- Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials?
- How do I talk to a friend or family member who needs treatment?
